Summary Report:
Stericycle Inc. announced its third quarter earnings with global revenues of $882.8 million, showing a slight decrease of 0.8% from the same period in 2016. However, when adjusted for various factors such as foreign exchange, acquisitions, and divestitures, organic revenue increased 0.2%. Domestic and Canada revenues were $708.2 million, with a decreased organic revenue of 0.2%. Moreover, international revenues were $174.6 million, and organic revenue decreased by 2.2%.

Gross profit was calculated at $368 million or 41.7% of revenues, while adjusted SG&A, excluding amortization, was $192.2 million or 21.8% of revenues. The adjusted income from operations or EBITDA was $175.9 million or 19.9% of revenues. Net interest expense stood at $24.5 million, and the company's as-reported tax rate for the quarter was 41.6% versus an adjusted tax rate of 36.9%. The net income attributable to Stericycle was $35.4 million or $0.41 on an as-reported basis and $1.10 when adjusted for acquisition-related expenses and other adjustments.

The company also provided details on its balance sheet, including a covenant debt to EBITDA ratio of 3.48 and having an unused portion of the revolver at approximately $712 million. Year-to-date cash from operations was $392 million, and adjusted cash from operations was $462.1 million. Year-to-date CapEx was $91.7 million or 3.4% of revenues, and the company's DSO was 64 days.

As per the earnings conference call, Stericycle revised its guidance for the fourth quarter, with an EPS range of $1.12 to $1.18. This adjustment was primarily due to various factors such as lower M&I volume, higher costs in Latin America, multiple hurricanes, and revenue impacts in EMEA. However, the company expects some favorability in benefit costs and lower interest rates to offset these impacts.

Stericycle also highlighted their preparations for renewing and extending their existing senior credit facility and term loans, taking advantage of current favorable debt markets and economic conditions.

Overall, based on the financial metrics discussed in the earnings conference call transcript, and considering the company's plans for renewal and extension of credit facility, we maintain an 'overweight' investment stance on Stericycle Inc. Despited the challenges faced in the third quarter, the company's global revenues and various offsetting factors provide potential for long-term growth.